Saturday, December 21, 2024
Home Biotech News CoronaVirus Page 11

CoronaVirus

    Latest
    Sorrento Theraputics, Biotech STock Review

    Adding Sorrento Therapeutics (SRNE) to CoronaVirus Watch List.

    Superbug News - CoronaVirus Watch List Editor / Curator -
    LIVE QUOTE Of course, we need not have to say, this is not an idea for widows...
    aPHEX bIOcLEANSE

    Hy-IQ Trademark

    Superbug News - CoronaVirus Watch List Editor / Curator -
    REGISTERED 9-15-2020
    Inovie, Biotech Stock Review

    Shorts Set $1.00 Price Target on Inovio (INO) $9.20.

    Infections Editor / Curator -
    Interesting battle brewing! LIVE CHART Inovio shares tumble 8%...

    Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in...

    CoronaVirus Editor / Curator -
    American Chemical Society May 2020. Higher rates of serious illness and death from coronavirus SARS-CoV-2...

    ‘Amazing potential.’ UM doctor to start stem cell trial for coronavirus patients (Miami Herald)

    CoronaVirus Editor / Curator -
    BY BEN CONARCK APRIL 16, 2020 A team of doctors at the University of Miami won emergency federal approval...
    Fletcher Robbe

    Dalrada (DFCO) Legal Counsel

    CoronaVirus Editor / Curator -
    WEBSITE CONTINUOUSLY UPDATED Dalrada Financial Adds Robbe to Board of DirectorsDalrada Financial Corporation Hires Fletcher...
    1...91011Page 11 of 11

    Latest article

    Adding Quantum Pharmaceutical (QNTM) $4.10 to Reverse Split Stock Watch List.

    All News Editor / Curator -
    119% Gain Post Split

    Nine Page Summary Report on GeoVax (GOVX)

    CoronaVirus Editor / Curator -
    This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

    GeoVax (GOVX) Provides First Half 2024 Business Update.

    CoronaVirus Editor / Curator -
    Award of BARDA Project NextGen contract represents a significant milestone event; Total value...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.